par Gnant, Michael;Baselga, José;Rugo, Hope;Noguchi, Shinzaburo;Burris, Howard H.A.;Piccart-Gebhart, Martine ;Hortobagyi, Gabriel N.;Eakle, Janice;Hart, Lowell L.L.;Mukai, Hirofumi;Iwata, Hiroji;Geberth, Matthias;Hadji, Peyman;El-Hashimy, Mona;Rao, Shantha;Taran, Tetiana;Sahmoud, Tarek;Lebwohl, David;Campone, Mario;Pritchard, Kathleen
Référence Journal of the National Cancer Institute, 105, 9, page (654-663)
Publication Publié, 2013-05
Référence Journal of the National Cancer Institute, 105, 9, page (654-663)
Publication Publié, 2013-05
Article révisé par les pairs
Titre: |
|
Auteur: | Gnant, Michael; Baselga, José; Rugo, Hope; Noguchi, Shinzaburo; Burris, Howard H.A.; Piccart-Gebhart, Martine; Hortobagyi, Gabriel N.; Eakle, Janice; Hart, Lowell L.L.; Mukai, Hirofumi; Iwata, Hiroji; Geberth, Matthias; Hadji, Peyman; El-Hashimy, Mona; Rao, Shantha; Taran, Tetiana; Sahmoud, Tarek; Lebwohl, David; Campone, Mario; Pritchard, Kathleen |
Informations sur la publication: | Journal of the National Cancer Institute, 105, 9, page (654-663) |
Statut de publication: | Publié, 2013-05 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Aged |
Alkaline Phosphatase -- blood | |
Androstadienes -- administration & dosage | |
Antineoplastic Agents -- pharmacology -- therapeutic use | |
Aromatase Inhibitors -- administration & dosage | |
Bone Density -- drug effects | |
Bone Density Conservation Agents -- pharmacology -- therapeutic use | |
Bone Neoplasms -- blood -- metabolism -- prevention & control -- secondary | |
Bone Remodeling -- drug effects | |
Bone Resorption -- drug therapy -- prevention & control | |
Breast Neoplasms -- blood -- chemistry -- pathology | |
Collagen Type I -- metabolism | |
Confounding Factors (Epidemiology) | |
Disease Progression | |
Disease-Free Survival | |
Drug Administration Schedule | |
Female | |
Follow-Up Studies | |
Fractures, Spontaneous -- etiology -- prevention & control | |
Humans | |
Middle Aged | |
Odds Ratio | |
Osteogenesis -- drug effects | |
Postmenopause | |
Procollagen -- blood | |
Proportional Hazards Models | |
Receptors, Estrogen -- analysis | |
Sirolimus -- analogs & derivatives -- pharmacology -- therapeutic use | |
TOR Serine-Threonine Kinases -- antagonists & inhibitors | |
Treatment Failure | |
Treatment Outcome | |
Note générale: | SCOPUS: ar.j |
Langue: | Anglais |
Identificateurs: | urn:issn:0027-8874 |
info:doi/10.1093/jnci/djt026 | |
info:pii/djt026 | |
info:scp/84877305137 | |
info:pmid/23425564 |